导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.02% | 3199/4773 |
| 近一周 | -2.35% | 1899/5462 |
| 近一月 | -3.53% | 1814/5421 |
| 近一季 | -7.89% | 2570/5209 |
| 近半年 | -9.35% | 3485/4920 |
| 近一年 | -0.84% | 2785/4366 |
| 近两年 | 38.86% | 1943/2954 |
| 近三年 | 19.46% | 1486/2253 |
| 成立以来 | 1.77% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.29% 1753/4961 |
8.38% 2597/5312 |
- - |
- - |
| 2025 | 24.94% 1749/4813 |
2.47% 1364/3635 |
4.21% 829/4076 |
15.80% 2772/4524 |
1.04% 1573/4813 |
| 2024 | -0.44% 2115/3463 |
-6.01% 1995/2808 |
-0.82% 847/3014 |
12.79% 2290/3129 |
-5.31% 2552/3463 |
| 2023 | -18.92% 1834/2656 |
-4.98% 2126/2280 |
-5.98% 1573/2385 |
-7.92% 1643/2515 |
-1.44% 327/2655 |
| 2022 | -24.82% 1262/2207 |
-17.23% 1190/1919 |
7.61% 447/2016 |
-10.56% 426/2113 |
-5.63% 1945/2208 |
| 2021 | 16.12% 281/1822 |
-5.63% 943/1255 |
18.58% 173/1330 |
8.36% 159/1466 |
-4.24% 1473/1822 |
| 2020 | 50.00% 172/1250 |
2.11% 137/1028 |
24.60% 168/1067 |
10.92% 498/1164 |
6.30% 763/1184 |
| 2019 | 16.21% 686/1092 |
25.12% 482/739 |
-11.73% 773/788 |
-2.55% 705/850 |
7.97% 374/918 |
| 2018 | -33.12% 545/834 |
- - |
-13.49% 447/631 |
-8.98% 499/660 |
-12.24% 429/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方大数据100C VS. 长安沪深300非周期A(740101) |